SMC Radiation Oncology

Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine

[SMC Radiation Oncology @SMC_RadOnc]

✅ Similar 4-yr bPFS: 80.1% vs 78.1%
✅ No difference in DMFS/CSS
⚠️ Higher late GI toxicity in HYPO arm, but all resolved
✅ Comparable QoL

📖 https://t.co/5htwkD3tlJ

#SMC_RadOnc #ProstateCancer #RadOnc

[SMC Radiation Oncology @SMC_RadOnc]

🎉 New Phase III RCT in @JCO_ASCO !

Hypofractionated (65Gy/26fx) vs conventional (66Gy/33fx) salvage RT after radical prostatectomy: the SHARE trial

Asan Medical Center × Samsung Medical Center collaboration 🤝
Congrats to co-first author Won Park & co-author Hongryull Pyo!

[SMC Radiation Oncology @SMC_RadOnc]

We interviewed 24 patients undergoing radiotherapy (HNC/HCC/lung ca) in Korea and identified 5 domains of unmet need, from communication gaps to accessibility barriers for long-distance patients.

📖 https://t.co/PITMOQ0hBy

#RadOnc #CancerCare #SMC_Rad_Onc

[SMC Radiation Oncology @SMC_RadOnc]

🤝 Our department signed an MOU with Varian Medical Systems Korea, a branch of @SiemensHealth, on July 8, advancing collaboration in cancer treatment innovation.
#SMC_RadOnc #Varian #SiemensHealthineers

[SMC Radiation Oncology @SMC_RadOnc]

🔬 New in Liver Cancer: Updated meta-analysis of IMRT vs SBRT vs PBT for HCC (80 studies, 6,655 pts).

SBRT & PBT > IMRT in efficacy. Optimal dose: BED 65–100 Gy.

With Dr. Hee Chul Park & Dr. Jeong Il Yu + Soonchunhyang, KIRAMS colleagues.

🔗 https://t.co/yojJXLkvtB

[SMC Radiation Oncology @SMC_RadOnc]

NSCLC + idiopathic pulmonary fibrosis = one of the highest-risk combos in thoracic RT.
Our prospective study (n=41) shows proton therapy can still deliver: G3+ toxicity 9.4% in early-stage disease, 1-yr LRC 93.2%.
https://t.co/2l95DpyI4q.
#LungCancer #RadOnc #SMC_RadOnc

[SMC Radiation Oncology @SMC_RadOnc]

📌 EBRT delivers overall survival comparable to resection & thermal ablation in early-stage HCC — supporting its role as a frontline treatment option.

Profs. Jeong-Il Yu & Hee Chul Park represented our department.

🔗https://t.co/f54XL8880j

[SMC Radiation Oncology @SMC_RadOnc]

🌍Samsung Medical Center contributed to the largest-ever international study on EBRT for hepatocellular carcinoma, just published in the Journal of Clinical Oncology. (n=4,913 · 30 centers · 11 countries)
#RadOnc #LiverCancer #HCC #SMC_RadOnc

[SMC Radiation Oncology @SMC_RadOnc]

🎗️ Our faculty at #GBCC2026 in Seoul!

🔹 Won Kyung Cho - Axillary surgery de-escalation & RT escalation in node-positive breast cancer

🔹 @lthoon0420 - Junior Doctors Debate

🔹 Haeyoung Kim — Risk-adapted RT for non-axillary regional nodes

#BreastCancer #RadOnc #SMC_RadOnc

[SMC Radiation Oncology @SMC_RadOnc]

Huge congratulations to @naleekim_rodr, Sang Hoon Seo, and Do Hoon Lim!

🔗 Read the full article here: https://t.co/ezFDFpRb6g

[SMC Radiation Oncology @SMC_RadOnc]

We introduce a novel deep learning platform for personalized circulating blood cell dosimetry during Craniospinal Irradiation, published in @IJROBP

#RadOnc #DeepLearning #PediatricOncology #SMC_RadOnc

[SMC Radiation Oncology @SMC_RadOnc]

Links:
🔗 https://t.co/uomG8RrHsw
🔗 https://t.co/uSlJ6p8Kh3

[SMC Radiation Oncology @SMC_RadOnc]

🔬 Two new publications from SMC Radiation Oncology this March!

📌 Repeat MDT in oligometastatic RCC defers systemic therapy with durable outcomes

📌 Adjuvant EBRT outperforms Gamma Knife in central neurocytoma

#RadOnc #SMC_RadOnc

[SMC Radiation Oncology @SMC_RadOnc]

Samsung Medical Center is now the FIRST in Korea to earn ICHOM Level 1 certification for breast cancer PRO measurement.
At our dept, this is already our daily reality — PROs via messaging app, integrated into our EHR!
#BreastCancer #RadOnc #SMC_RadOnc
https://t.co/iJX9WdAgoR

[SMC Radiation Oncology @SMC_RadOnc]

Our team just held our 2025 Patient Safety Committee annual review. 🏥
The goal: spot risks before they become incidents. Proactive reporting. Preventive thinking. A culture of safety.
Because the best safety event is the one that never happens.
#RadOnc #SMC_RadOnc

[SMC Radiation Oncology @SMC_RadOnc]

Links:
🔗 https://t.co/RXht7Fiazt
🔗 https://t.co/FtbrwOAolP

[SMC Radiation Oncology @SMC_RadOnc]

📚 Feb Recap #2

🔹Endorectal balloon use linked to higher rectal bleeding risk after hypofractionated IMRT for prostate cancer
🔹 LVI + RCB class refines risk stratification in residual TNBC after neoadjuvant therapy

#RadOnc #SMC_RadOnc

[SMC Radiation Oncology @SMC_RadOnc]

Links:
🔗 https://t.co/TKst6aVNYR
🔗 https://t.co/ovvmsmOuq4
🔗 https://t.co/YNGtpeTVGe

[SMC Radiation Oncology @SMC_RadOnc]

📚 Feb Recap #1

🔹SABR+ICI vs TKI in metastatic HCC — well tolerated, but more grade ≥2 late AEs with ICI
🔹Proton therapy treatment time optimization via dynamic range optimization
🔹Hypofractionated preop RT feasible in retroperitoneal sarcoma

#RadOnc #SMC_RadOnc

[SMC Radiation Oncology @SMC_RadOnc]

New from Samsung Medical Center! 🌟 Study of 2,000 HCC cases in Eur J Cancer: 2-yr freedom from local progression >90% with Proton Beam Therapy! Congrats authors Dr. Lee JH, Dr. Yu JI & Dr. Park HC! 👏

https://t.co/RHqnjM4HH7

#LiverCancer #ProtonTherapy #HCC #RadOnc #SMC_RadOnc